2 min read

Unique Challenges in Recruiting Patients for Rare Indication Pediatric Studies: Overcoming Difficulties through a Site and CRO Perspective

Don't miss Veristat’s plenary presentation at the World Orphan Drug Congress (WODC), Barcelona, Thursday, October 24th at 12:10 pm CET:


"Unique Challenges in Recruiting Patients for Rare Indication Pediatric Studies: Overcoming Difficulties through a Site and CRO Perspective"

Recruiting patients for rare pediatric studies presents unique challenges that require specialized strategies. This session will delve into the complexities of patient recruitment in rare pediatric populations from a CRO perspective as well a world-leading pediatric clinical site: Sant Joan de Déu. Insights and lessons will include:

  • Effective pediatric rare disease recruitment strategies
  • Concierge level patient support to reduce patient burden
  • Embedding Clinical Research into a hospitals core strategy
  • Holistic approach to patient and family care
  • Aligning Government Policy to help with recruitment
  • Utilization of real-world protocol simulations to avoid costly protocol amendments

 The presentation is filled with actionable insights, with time allowed for your questions to be answered. Don't miss this opportunity to connect with our Experts and learn how Veristat is making a difference in the lives of patients with rare and ultra-rare diseases.

Thursday, October  24 at 12.10 PM CET

Meet the Speakers

Joana Head shot ok

Joana Claverol Torres

Clinical Research Director , Sant Joan de Déu Research Foundation
Joana Claverol, is the Clinical Research Director at Barcelona Children’s Hospital Sant Joan de Déu, Spain, where she leads the clinical trials office since 2012 and the Patients engagement in research area since 2015. The Clinical Research Unit is a reference unit for pediatric patients nationally and internationally, specializing in innovative treatments for highly complex patients with rare pediatric diseases. She has more than 13 years of experience in medical and clinical research in the pharmaceutical and biotechnology industry, with special knowledge and experience in drug development and clinical trial design, and all regulatory and methodological aspects related to clinical research. She holds a postgraduate in Senior Management Program of Health Institutions by IESE Business School, a Master in Pharmaceutical Marketing by Universitat Pompeu Fabra, a Master of clinical trials at Universitat de Barcelona and a BS Degree in Biological Sciences by Universitat Autonoma de Barcelona.
Rachel Headshot Ok

Rachel Abu Taleb

Medical Monitor, Veristat
Rachel Abu Taleb, M.D, is Medical Monitor at Veristat and a pediatrician by training and education, bringing significant expertise in vaccine clinical trials, responsible for all areas of medical monitoring of studies including patient safety, data integrity, and cross-functional collaboration.

Veristat at the  WODC Conference

Find us at Booth 35 where we invite you to stop by and discover more about what makes Veristat a distinguished name in the clinical research industry. Our team will share insights and answer questions you might have about our Science-First approach that delivers several benefits to sponsors including the right design, reliable trial execution, and successful study completion to support rapid approval. 

Schedule A Meeting

You can arrange a meeting by completing the form on the right side of this page. Discover how we can assist you in progressing your upcoming clinical trial or regulatory submission towards a successful outcome or explore our wide range of capabilities. 

Conference Details

Website: WODC Congress EUROPE 2024

 

 

 

 

 

 

Share This Event:

   

1 min read

Fierce Biotech Summit 2024

Meet Veristat in Boston at the Fierce Biotech Summit Conference | September 30 - October 1 in Boston, Massachusetts

We...

4 min read

Unique Challenges in Recruiting Patients for Rare Indication Pediatric Studies: Overcoming Difficulties through a Site and CRO Perspective

Don't miss Veristat’s plenary presentation at the World Orphan Drug Congress (WODC), Barcelona, Thursday, October 24th...